It is essential for clinicians to remain informed on upcoming clinical trials conclusions and the resulting data that may inform therapeutic strategies, affect clinical guidelines, expand treatment options, and ultimately improve patient quality of life.

The following clinical trials are Phase 3 trials based in the United States. All trials have anticipated primary completion dates prior to December 31, 2027, and are sorted by start date. At the time of this writing, five of the eight trials are still recruiting. Consult the study details and source links for more information regarding the eligibility criteria.

Quick View Table of Lymphoma Clinical Trials
Study TitleRecruiting?Estimated EnrollmentStart DateEstimated Primary Completion
A Clinical Trial Evaluating Patients With Primary Vitreoretinal LymphomaYes20February 2026December 2026
Study of Tirabrutinib vs Rituximab/​Temozolomide for Relapsed/​Refractory Primary Central Nervous System Lymphoma (PCNSL) (IGNITE)Yes132February 2026December 2027
Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL (FLASH2)Yes80January 2025July 2026
Soquelitinib vs Standard of Care in Participants With Relapsed/​Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell LymphomaYes150October 2024November 2026
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/​Refractory Mantle Cell Lymphoma (GLOBRYTE)Yes182October 2023August 2027
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell LymphomaNo1130September 2023December 2027
A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/​Small Lymphocytic Lymphoma (CLL/​SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)No300March 2023May 2027
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (EPCORE DLBCL-2)No900February 2023June 2027
Lymphoma Clinical Trials in the United States Anticipated to Complete By December 2027

A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma

  • Sponsor: Aldeyr Therapeutics, Inc.
  • Goal: A prospective, randomized, double-masked, dosing-frequency-controlled, multicenter clinical trial evaluating the safety and activity of intravitreally injected ADX-2191 (methotrexate injection USP) in patients with primary vitreoretinal lymphoma.
  • Interventions: ICM ADX-2191 injection, monthly ADX-2191 injection
  • Primary Outcome Measure: Proportion of clearance of lymphomatous vitreous cells compared across ICM and monthly ADX-2191 treatment groups after eight weeks of treatment.
  • Time Frame: Eight weeks.
  • Study Details
  • Source

Study of Tirabrutinib vs Rituximab/​Temozolomide for Relapsed/​Refractory Primary Central Nervous System Lymphoma (PCNSL) (IGNITE)

  • Sponsor: Ono Pharmaceutical Co. Ltd
  • Goal: The purpose of this clinical trial is to evaluate efficacy and safety of tirabrutinib alone compared with rituximab and temozolomide (R-TMZ) combination therapy in participants with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL).
  • Interventions: Tirabrutinib, rituximab, temozolomide
  • Primary Outcome Measure: Progression free survival
  • Timeframe: Estimated up to 24 months
  • Study Details
  • Source

Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL (FLASH2)

  • Sponsor: Soligenix
  • Goal: To evaluate the use of HyBryte, a topical photosensitizing agent, to treat patients with patch/plaque phase cutaneous T-cell lymphoma (mycosis fungoides).
  • Interventions: Hypericin, placebo
  • Primary Outcome Measure: Number of participants with a treatment response in the modified composite assessment of index lesion disease severity (MCAILS) score
  • Time frame: 18 weeks
  • Study Details
  • Source

Soquelitinib vs Standard of Care in Participants With Relapsed/​Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

  • Sponsor: Corvus Pharmaceuticals
  • Goal: A Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapsed/refractory (R/R) peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), follicular helper T-cell lymphomas (FHTCLs), or systemic anaplastic large-cell lymphoma (sALCL).
  • Interventions: Soquelitinib, belinostat, pralatrexate
  • Primary Outcome Measure: Progression-free survival
  • Timeframe: Up to four years post study treatment initiation
  • Study Details
  • Source

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/​Refractory Mantle Cell Lymphoma (GLOBRYTE)

  • Sponsor: Hoffmann-La Roche
  • Goal: The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).
  • Interventions: Obinutuzumab, glofitamab, rituximab, bendamustine, lenalidomide, tocilizumab
  • Primary Outcome Measure: Progression-free survival
  • Timeframe: From randomization to the first occurrence of disease progression or death from any cause (up to approximately 24 months).
  • Study Details
  • Source

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

  • Sponsor: Hoffmann-La Roche
  • Goal: The purpose of this study is to compare the efficacy and safety of glofitamab in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs Pola-R-CHP in participants with previously untreated CD20-positive large B-cell lymphoma (LBCL).
  • Interventions: Glofitamab, polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, prednisone
  • Primary Outcome Measure: Progression-free survival (PFS) as determined by Independent Review Facility (IRF)
  • Timeframe: From randomization to the first occurrence of disease progression or relapse, or death due to any cause, whichever occurs first (up to approximately 65 months)
  • Study Details
  • Source

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (EPCORE DLBCL-2)

  • Sponsor: Genmab
  • Goal: The purpose of this study is to assess the change in disease activity of epcoritamab when combined with intravenous and oral rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP) or R-CHOP in adult participants globally with diffuse large b-cell lymphoma (DLBCL).
  • Interventions: Epcoritamab, cyclophosphamide, rituximab, vincristine, doxorubicin, prednisone
  • Primary Outcome Measure: Number of participants with progression-free survival (PFS) with an international prognostic index (IPI) of 3-4.
  • Timeframe: Up to approximately 46 months.
  • Study Details
  • Source

Related Guidelines:

Sign up for alerts and stay informed on the latest published guidelines.

Copyright © 2026 Guideline Central, all rights reserved.